secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0000012208-24-000062
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q3 revenue up 2.8% to $649.7M; net income $653.2M on Sartorius gain
---------------------------------------------------------------------------

- Net sales $649.7M, +2.8% YoY; currency-neutral +3.4%; Clinical Diagnostics grew 5.6% to $388.8M.
- Life Science segment sales $260.9M, -1.0% YoY, citing ongoing biotech/biopharma weakness.
- Income from operations fell to $64.5M from $90.9M; net income surged to $653.2M ($23.34 EPS) on Sartorius fair value change.
- Gross margin improved to 54.8% from 53.1% YoY; effective tax rate 24.2%.
- Appointed Jon DiVincenzo as President and COO; CEO cites gradual biopharma recovery and new leadership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220824000062/0000012208-24-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220824000062/bio-20241030.htm
  HTML page:      https://secwatch.observer/filing/0000012208-24-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer